X-linked Tumor Suppressor Escape and Sex Dimorphism in Cancer: Implications for Risk Stratification and Prevention.
- 1Department of Chemistry, College of Science and Technology, Duksung Women's University Seoul Korea.
Abstract
Epidemiological data demonstrate a marked male bias in incidence and mortality across most non-reproductive cancers. Beyond behavioral and hormonal factors, recent genomic insights highlight the critical role of X-chromosome genetics and epigenetics. Specifically, genes that escape X-chromosome inactivation (XCI)-termed Escape from X-Inactivation Tumor Suppressors (EXITS)-provide a female-specific "dosage protection" mechanism against oncogenesis. This review analyzes seven X-linked tumor suppressor genes associated with sex-biased cancer phenotypes (KDM6A, KDM5C, DDX3X, ATRX, PHF6, MAGEC3, and CNKSR2) and their roles in cancer etiology and tumor suppression. Under the two-hit hypothesis, female cells-with two X chromosomes-can offset a loss-of-function mutation on the active X chromosome through normal allele expression from the inactive X chromosome (Xi), lowering susceptibility. Conversely, males with only one X chromosome face a "single-hit vulnerability," in which a single loss-of-function mutation disrupts the tumor-suppressor network. We further note persistent knowledge gaps regarding the remaining X-linked tumor suppressors annotated in the TSGene 2.0 database, reflecting the facultative nature of XCI escape, limited statistical power in existing cohorts, and the underuse of single-cell multi-omic approaches. Elucidating XCI escape and X-linked gene dosage imbalances offers a framework for sex-specific precision oncology. For high-risk male populations, identifying EXITS gene mutations warrants more intensive, shorter-interval screening. In female patients, epigenetic modulators that induce X-reactivation of Xi may offer unique therapeutic benefits. Incorporating X-linked gene dosage parameters into clinical trials and drug development will be essential to overcome sex disparities in cancer prevention and therapy.
Related
- Assessing clinical utility of genomic risk stratification for cancer prevention: a systematic review
- Maternal gut microbiota, tryptophan metabolism and immune homeostasis: Implications for the prevention of adverse pregnancy complications
- Plasma proteomic signatures in bipolar disorder and their implications for data-driven patient stratification
- Artificial Intelligence in suicide prevention: promise, peril, and clinical implications for clinical practice
- Impact of diet on inflammatory bowel disease risk: systematic review, meta-analyses and implications for prevention
BibTeX
@article{han2026xlinked,
title = {{X-linked Tumor Suppressor Escape and Sex Dimorphism in Cancer: Implications for Risk Stratification and Prevention.}},
author = {Sori Han and Sun Young Kim},
journal = {Journal of cancer prevention},
year = {2026},
month = oct,
doi = {10.15430/jcp.26.041},
url = {https://europepmc.org/article/MED/42996556},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - X-linked Tumor Suppressor Escape and Sex Dimorphism in Cancer: Implications for Risk Stratification and Prevention.
AU - Sori Han
AU - Sun Young Kim
PY - 2026
DA - 2026/10/01
JO - Journal of cancer prevention
DO - 10.15430/jcp.26.041
UR - https://europepmc.org/article/MED/42996556
AB - Epidemiological data demonstrate a marked male bias in incidence and mortality across most non-reproductive cancers. Beyond behavioral and hormonal factors, recent genomic insights highlight the critical role of X-chromosome genetics and epigenetics. Specifically, genes that escape X-chromosome inactivation (XCI)-termed Escape from X-Inactivation Tumor Suppressors (EXITS)-provide a female-specific "dosage protection" mechanism against oncogenesis. This review analyzes seven X-linked tumor suppressor genes associated with sex-biased cancer phenotypes (KDM6A, KDM5C, DDX3X, ATRX, PHF6, MAGEC3, and CNKSR2) and their roles in cancer etiology and tumor suppression. Under the two-hit hypothesis, female cells-with two X chromosomes-can offset a loss-of-function mutation on the active X chromosome through normal allele expression from the inactive X chromosome (Xi), lowering susceptibility. Conversely, males with only one X chromosome face a "single-hit vulnerability," in which a single loss-of-function mutation disrupts the tumor-suppressor network. We further note persistent knowledge gaps regarding the remaining X-linked tumor suppressors annotated in the TSGene 2.0 database, reflecting the facultative nature of XCI escape, limited statistical power in existing cohorts, and the underuse of single-cell multi-omic approaches. Elucidating XCI escape and X-linked gene dosage imbalances offers a framework for sex-specific precision oncology. For high-risk male populations, identifying EXITS gene mutations warrants more intensive, shorter-interval screening. In female patients, epigenetic modulators that induce X-reactivation of Xi may offer unique therapeutic benefits. Incorporating X-linked gene dosage parameters into clinical trials and drug development will be essential to overcome sex disparities in cancer prevention and therapy.
SN - 2288-3649
SN - 2288-3657
ER -